An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy

NCT02069535 Phase 2 COMPLETED

This trial is an open, national, multi-centre trial. The main objective of this trial is to assess the tolerability of the up-dosing phase of AVANZ® Cupressus arizonica by measurement of related Adverse Events.

Details

Lead sponsor	ALK-Abelló A/S
Phase	Phase 2
Status	COMPLETED
Enrolment	52
Start date	2014-04
Completion	2014-11

Conditions

• Allergic Rhinoconjunctivitis

Interventions

• AVANZ Cupressus

Primary outcomes

• Frequency of patients with IMP-related AEs — 6 treatment weeks

Countries

Spain